MHRA Drug Safety Update Risperidone & paliperidone:risk of intraoperative floppy iris syndrome in patients undergoing cataract surgery
The Medicines and Healthcare Products Regulatory Agency has issued a Drug Safety Update to alert medical professionals to cases of intraoperative floppy iris syndrome (IFIS) during cataract surgery reported in patients taking the atypical antipsychotics risperidone or paliperidone. IFIS may increase the risk of eye complications during and after cataract surgery Risperidone & paliperidone:risk of
Intravitreal ranibizumab injection for the treatment of choroidal neovascularisation secondary to pathological myopia
College Statement The Royal College of Ophthalmologists welcomes the decision by The National Institute for Health and Care Excellence (NICE) to recommend Ranibizumab 0.5 mg intravitreal injection as an option for treating visual impairment due to choroidal neovascularisation secondary to pathological myopia. Prior to this decision there has been limited / variable access to anti-VEGF
NHS England: College’s guidance will help to reduce avoidable sight loss
Dr David Geddes, Head of Primary Care Commissioning for NHS England, has urged health commissioners to use new guidance published today by the College of Optometrists and the Royal College of Ophthalmologists to improve the quality and efficiency of eye health services. Dr Geddes says: “We can now treat more and more of the diseases
Setting Priorities for Eye Research Final Report
The College has been involved in the Sight Loss and Vision Priority Setting Partnership. This report was published in October 2013. Sight Loss and Vision Priority Setting Partnership FINAL REPORT
NICE rapid review of the use of fluocinolone acetonide for chronic DMO
College Statment Since the release of TA 2711 in January 2013, NICE has undertaken a rapid review of the use of fluocinolone acetonide for chronic diabetic macular oedema2 and has recently released the FAD document for this single technology appraisal3. In the FAD document, the following guidance has been issued: Fluocinolone acetonide intravitreal implant is